Date: 2013-01-21
Type of information: Development agreement
Compound: new production animal antiparasitic vaccines
Company: Merial (France) Vitamfero (France)
Therapeutic area: Veterinary medicine
Type agreement: development
licensing
commercialisation
Action mechanism:
Disease:
Details: VitamFero, a biotechnology firm backed by Genopole® with a second facility in Tours, has announced a partnership agreement with Merial, the Animal Health Division of Sanofi Group, for developing new vaccines against significant production animal parasites. Merial, a world leader in animal health, has a 12 month option to finalize with VitamFero an exclusive, global license for developing, registering, producing and marketing certain of VitamFero\'s antiparasitic vaccines. According to the terms of the agreement reached, in the period before the option is exercised, Merial will participate in funding development operations.
VitamFero\'s vaccines covered by this partnership are developed from a unique process pioneered by VitamFero to create vaccines which are highly efficacious but with a safety profile that allows them to be effective tools in the control of these potentially devastating diseases.
Financial terms:
Latest news:
